Amgen Inc. $AMGN Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 333,529 shares of the medical research company’s stock after acquiring an additional 48,384 shares during the quarter. Schroder Investment Management Group owned approximately 0.06% of Amgen worth $91,377,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after purchasing an additional 165,281 shares in the last quarter. State Street Corp lifted its position in shares of Amgen by 0.6% during the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after purchasing an additional 177,035 shares during the last quarter. Geode Capital Management LLC grew its stake in Amgen by 2.3% in the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after purchasing an additional 291,271 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares in the last quarter. Finally, Laurel Wealth Advisors LLC increased its holdings in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after buying an additional 6,676,575 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 2.0%

NASDAQ:AMGN opened at $376.97 on Tuesday. The stock has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The business has a fifty day moving average of $354.21 and a 200-day moving average of $323.38.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Analyst Ratings Changes

Several brokerages have issued reports on AMGN. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Argus upped their price target on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, DZ Bank raised their price objective on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $354.17.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.